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Disruption of axonal integrity during injury to the peripheral nerve system (PNS) sets into motion a cascade of responses that
includes inflammation, Schwann cell mobilization, and the degeneration of the nerve fibers distal to the injury site. Yet, the
injured PNS differentiates itself from the injured central nervous system (CNS) in its remarkable capacity for self-recovery, which,
depending upon the length and type of nerve injury, involves a series of molecular events in both the injured neuron and associated
Schwann cells that leads to axon regeneration, remyelination repair, and functional restitution. Herein we discuss the essential
function of the second messenger, cyclic adenosine monophosphate (cyclic AMP), in the PNS repair process, highlighting the
important role the conditioning lesion paradigm has played in understanding the mechanism(s) by which cyclic AMP exerts its
proregenerative action. Furthermore, we review the studies that have therapeutically targeted cyclic AMP to enhance endogenous
nerve repair.
1. Introduction
Injury to the peripheral nerve system (PNS), leading to
motor, sensory, and/or autonomic functional loss, is not
uncommon yet remains a challenge for surgeons. Peripheral
nerves (PNs) can experience injury by way of stretch, lac-
eration, compression and mechanical deformation, with the
regenerative capacity of the nerves under each circumstance
varying accordingly [1]. Unlike injury to the central nervous
system (CNS), however, injury to the PNS induces a gene
expression program that, in many cases, ultimately leads
to self-recovery through axon regeneration and reconnec-
tion. With rare exception, PNs will maintain accuracy and
reproducibility of connections after crush injury [2]. Yet,
in the event of complete nerve laceration, the fidelity of
axon regeneration is no longer guaranteed. In this case,
the current “gold standard” of treatment requires that the
space between nerve endings, also commonly referred to
as the “nerve gap,” either be bridged or filled in with an
entirely new distal pathway. Currently, surgical management
of the gap includes the placement of a nerve autograft, nerve
conduit, acellular nerve allograft, and for more severe and/or
proximal nerve injuries, cellular nerve allografts and nerve
transfers. Each surgical management strategy attempts in
its own way to create a more ideal conduit by which the
peripheral axons can return to their denervated targets and
form functional synapses—a necessity for the restoration of
function. Challenges to achieving full recovery in such a
paradigm arise primarily due to the nature of the unilateral
approach to therapy. In only targeting the extrinsic variables
of regeneration, the success of the PN repair process becomes
dependent primarily upon several potentially uncontrollable
variables, such as the time-delay between injury and graft
placement, the age of the patient, and the distance separating
the nerve endings, rather than on the efficacy of the healing
modalities available [1].
Over time, our understanding of the PN regeneration
process has increased significantly.Wenowknow that injured
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axons form proximal regenerative buds that, in a process
largely governed by factors produced by Schwann cells (SCs),
sprout and grow toward their distal targets. Furthermore,
the importance of degeneration as the rate limiting step
in the process of recovery has also been elucidated. After
PNS injury there is exponential migration of microglia and
macrophages to the lesion site for the purpose of removing
debris [3].This process clears the path for the growing axons.
Once the debris is cleared, the proximal end of the injured
axon sprouts regenerative buds. In the meantime, Wallerian
degeneration occurs at the distal end of the injured axons, a
process that includes degeneration of the axons and myelin,
but not the endoneurium, which later serves as a conduit
to direct axon growth back to their correct targets. The
molecular mechanisms governing these responses have been
a major focus of investigation over the last decade, producing
a greater understanding of the signaling events in both
neuron and glia that govern successful regeneration as well
as offering novel targets for the development of therapeutic
interventions (reviewed in [1, 4, 5]). A primary mediator of
this intrinsic growth response of peripheral axons [6] is the
second messenger, cyclic adenosine monophosphate (cyclic
AMP), which is essential to PNS regeneration for both axon
and SC responses.
2. Neuronally Expressed Cyclic AMP
Signaling Intermediaries Involved in
Nerve Regeneration
Injury to the PNS switches the neuron’s function from the
provision of neurotransmission to the musculature back
to its developmental role of axon growth [7]. After the
PN is injured, its cytoplasm is exposed to the extracellular
environment, permitting calcium and sodium ions to freely
flow into the axon through the ruptured plasma membrane.
The unregulated flow of ions alters the membrane potential
such that it becomes capable of generating a multitude of
action potentials at the site of injury. These action potentials
propagate in a retrograde manner to the cell body where
the discharge promotes another influx of calcium through
voltage-dependent ion channels. The influx of calcium at the
site of axotomy and through voltage-gated calcium channels
in turn promotes the activation of a variety of proteins.
This activation continues temporally as subsequent waves
of stimulating signals from the injured axons and from
associated glial cells are retrogradely relayed to the neuronal
somata. There has been work to show that this response
to injury is quite different between the PNS and CNS and
thus may account for the differences in the regenerative
capabilities of the two systems [8].
One of the proteins activated by these signals is
membrane-bound adenylyl cyclase, which converts adeno-
sine triphosphate (ATP) to the second messenger, cyclic
AMP [9, 10]. The production of cyclic AMP alters the
physiology of the neuron, changing its function from one
of transmission to one of growth through a series of down-
stream effectors (Figure 1). The effect of cyclic AMP to
alter the intrinsic capacity of neurons to regenerate their
axons can be recapitulated by the injection of a cyclic AMP
synthetic analog, such as dibutyryl-cyclic AMP (db-cyclic
AMP), into the dorsal root ganglion [11, 12]. It has been
shown that the transcription-dependent effects of cyclic AMP
on regeneration occur through both PKA-dependent [13]
and PKA-independent signaling, via cyclic AMP activation
of the cytokine interleukin 6 (IL-6) gene [14]. The PKA-
independent pathway through IL-6 has been shown to
involve IL-6 binding to the IL-6R and gp130 receptor and
coreceptor, respectively. Receptor binding activates the Janus-
Activated Kinase (JAK) family of tyrosine kinases [15]. JAK
activation by IL-6 can allow neurites to overcome growth
inhibition in response to myelin-associated glycoprotein
(MAG) and myelin. The ultimate transcriptional target of
IL-6 signaling is the transcription factor, signal transducer
and activator of transcription 3 (STAT-3) [16], hypothesized
to allow the transmission of retrograde signals from the
axotomized axon to the nucleus to induce gene programs
involved in neuronal survival and regeneration after nerve
injury [17]. The necessity of IL-6 for cyclic AMP-mediated
axonal regeneration, however, remains unclear, as blocking
IL-6 signaling produces no effect on the ability of cyclic AMP
to overcome axon growth inhibition bymyelin inhibitors [14].
This work demonstrated that IL-6 was sufficient to overcome
myelin inhibition of axon growth yet not necessary for the
effects of cyclic AMP. However, Cafferty et al. reported that,
following a conditioning lesion in IL-6 knock-out animals, no
dorsal column axonal regeneration occurs, thus highlighting
the importance of IL-6 as an effector of cyclic AMP in
neuroregeneration [18].
The PKA-dependent pathway involved in cyclic AMP-
mediated axon growth over inhibitory substrates, on the
other hand, requires the downstream activation of several
key transcription factors, cyclic AMP responsive element
binding protein (CREB), activating transcription factor type
III (ATF-3), and STAT-3 [19–22]. Both STAT-3 and ATF-
3 have been shown to influence DRG neurite regeneration
and elongation. ATF-3 has demonstrated proregenerative
qualities when neurons are cultured on permissive substrates,
such as laminin [21, 23, 24]. ATF-3, however, is not sufficient
to overcome the inhibitory effects of myelin nor is it able
to promote central axonal regeneration in the spinal cord in
vivo [21]. In contrast, the activation of CREB alone has been
shown to be sufficient for overcoming myelin’s inhibition
of neurite outgrowth [13]. While activation of the intrinsic
growth capacity of neurons through cyclic AMP occurs at
the transcriptional level to promote axonal elongation, the
regenerative effects of cyclic AMP and PKA can also affect
axonal growth through direct effects on cytoskeletal behavior
[13, 25].
PKA can directly alter cytoskeletal effectors at the axon
to stimulate growth by way of disinhibition. Thus far, three
major inhibitors of neurite growth have been identified in
myelin, Nogo, Ogmp, and MAG, the last of which appears
to be the main inhibitory component of PN myelin [26–
28]. It has been demonstrated that MAG activates the small
GTPase, Rho-A, in a p75NTR dependent manner [29]. The
Rho-A GTPase signals through activation of Rho-associated
kinase (ROCK) to inhibit axon cytoskeletal assembly [30, 31].
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Figure 1: Following PN injury, cyclic AMP is involved in a variety of positive (green line), inhibitory (red line), and as yet to be identified
(dashed line) signaling mechanisms within the injured neurons and their accompanying glia that culminates in PN regeneration.
While studies to date in nonneuronal cells have suggested that
PKA may phosphorylate Rho-A and negatively regulate its
activity, it is unclear whether this mechanism occurs in cyclic
AMP-PKA-mediated relief of neurite outgrowth inhibition
onmyelin. It has been shown, however, that after nerve injury,
the activation of GTP-bound Rho-A, which is normally
undetectable in intact ganglia, is dramatically upregulated
in peripheral neurons [30]. Furthermore, ROCK inhibi-
tion using fasudil, a selective RhoA/Rho kinase (ROCK)
inhibitor, after nerve injury, has been shown to facilitate
repair as detected by way of amplitude measurements of
distally evoked compound muscle action potentials, which
were faster after axonal injury in mice treated with fasudil
[30, 31].The transcriptional-dependent mechanisms of cyclic
AMP-PKA-induced axon growth have been also shown to
regulate cytoskeletal assembly through CREB activation of
the gene arginase-1 and ensuing polyamine synthesis [25].
Wolff [32] demonstrated that the rate and extent of micro-
tubule assembly from nervous system tubulin are enhanced
by oligocations including polyamines. Polyamines, through
arginase-1, promote neuronal cytoskeletal assembly via tubu-
lin stimulation [32]. Arginase 1 is upregulated after a periph-
eral lesion and is a rate-limiting enzyme in the synthesis
of the polyamines putrescine, spermidine, and spermine,
which together are essential for axon cytoskeleton assembly
[25]. The importance of polyamine synthesis in cyclic AMP-
mediated neurite growth on MAG and myelin has been
demonstrated in inhibition studies, while overexpression
of arginase has been shown to overcome neurite growth
inhibition by MAG and myelin [25].
3. The Molecular Role of Cyclic AMP in
Schwann Cell Responses during PN Repair
After PN injury, Schwann cells (SCs) undergo a series of
cellular changes that include dedifferentiation, proliferation,
and then differentiation back to a myelinating phenotype.
The transition between these stages and the functionality of
the SCs within each rely heavily on cyclic AMP signaling.
Initial physical damage to the PN triggers a cellular response
of immune cells and SCs in the distal nerve termedWallerian
degeneration. During this process the SCs lose their myelin
sheaths and undergo dedifferentiation. This allows the SCs
to subsequently proliferate in response to signals from the
regenerating axons to ensure that sufficient numbers of SCs
are generated to replace those lost during injury and to allow
them to mediate remyelination repair. The initial changes
in SCs as they undergo dedifferentiation, their proliferation
and association with axons, and their differentiation and
remyelination of axons have all been shown to involve cyclic
AMP signaling [33–35].
Studies have demonstrated that cyclic AMP is important
for SC replication through its positive interaction with
receptor tyrosine kinases (RTKs) [35, 36]. Platelet-derived
growth factor (PDGF), basic fibroblast growth factor (bFGF),
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insulin-like growth factor (IGF), and regenerating protein
1 (Reg-1) all promote SC proliferation, but only when they
are added in conjunction with cyclic AMP or an agent that
promotes elevated cyclic AMP levels, such as forskolin [35, 37,
38]. Members of the neuregulin family of growth factors, on
the other hand, function in a self-reliant manner to promote
the proliferation of SCs [33, 39], but do so only because they
promote the accumulation of endogenous cyclic AMPwithin
the cell.
The cyclicAMP-dependent processes involved in the ded-
ifferentiation and proliferation of SCs occur either through
its direct activation of PKA, or due to its role as a “gating”
molecule, by regulating the flow of signals through other
pathways. Kim and colleagues (2001) showed that when SCs
are cultured in PDGF-free medium, they become growth-
arrested, with a diploid (G1) content of DNA. Furthermore,
although PDGF is a positive signal for DNA replication and
division of SCs, PDGF-treated SCs do not progress through
the G1 phase of the cell cycle toward S phase until they are
exposed to cyclic AMP. In the same study it was demonstrated
that PKA activity in SCs undergoing proliferation maintains
the expression of cyclin D1 after the initial mitogenic cue
has been given by a receptor tyrosine kinase. Importantly,
the proliferation of mature SCs is strictly dependent upon
the expression of cyclin D1 [40]; however, the mechanism
by which forskolin sustains and reinitiates cyclin D1 was not
elucidated in this work. In contrast, neuregulin-induced SC
proliferation, in which this signal alone increases cyclic AMP,
has been reported by Monje and colleagues (2008) to involve
a more complex interaction in which the effect of cyclic AMP
on S-phase entry relies also on the ability of the second
messenger to enhance the effects of neuregulin-stimulated
MEK-ERK and PI3K-Akt activation, both of which are
required for progression of the cell cycle. The activation of
PKA is still ultimately required for triggering S-phase entry
of SCs by concomitantly enhancing the ligand-dependent
tyrosine phosphorylation and activation of the neuregulin
coreceptor, ErbB2-ErbB3 [34].
How cyclic AMP regulates the SC’s response to injury is
unique, however, in that cyclic AMPcan act as both amitogen
and as a differentiation signal. In addition to promoting SC
proliferation, cyclic AMP signaling also mediates the exit of
SCs from the cell cycle by way of their transformation into
a premyelinating phenotype [36]. Elevation of cyclic AMP
promotes the expression of the transcription factor Krox-
20 (otherwise known as Egr2), which drives the expression
of an array of myelin-related proteins and lipids, as well as
transcription factors including Oct-6 and NF-𝜅B [41–44].
Although Krox-20 null SCs have been shown to express
the early myelin marker, myelin-associated glycoprotein
(MAG), they fail to ensheathe axons and do not upregulate
myelin basic protein (MBP) [41]. Mirsky and coworkers [45]
showed that, in the presence of cyclic AMP, Krox-20 null
SCs still express the protein periaxin, which is required
for the maintenance of myelin [45]. Furthermore, periaxin
is expressed in these mice after PN injury, indicating that
important myelin-associated genes can be regulated by cyclic
AMP through both Krox-20-dependent and -independent
mechanisms.
This seeming contradictory function of cyclic AMP as
both a mitogen and in promoting differentiation has been
suggested to result from the two main downstream effector
pathways of cyclic AMP, PKA and the exchange protein
activated by cyclic AMP (EPAC) [46]. This question was
recently examined in studies by Bacallao and Monje (2013)
in which they showed that SC dedifferentiation and prolifera-
tion required PKA activation, not EPAC,while differentiation
into myelin-forming cells involved EPAC rather than PKA.
EPAC is able to directly transduce cyclicAMP signals through
its ability to act as a guanine nucleotide exchange factor for
the small GTP-binding protein Rap1. In this work, however,
EPAC activation alone was demonstrated to be sufficient nei-
ther for a full differentiating response, nor for the expression
of Krox-20, suggesting that more work needs to be done to
identify themolecular effectors of cyclicAMP in the initiation
of SC differentiation [47].
4. The Conditioning Lesion as a Paradigm for
Regenerative Strategies
Following PN injury, functionally meaningful regeneration
requires that the injured axons regrow to reinnervate their
denervated targets through the formation of functional
synapses and that these axons are then remyelinated to allow
for proper axon conduction. However, current therapeutic
strategies, in particular surgical interventions, are often insuf-
ficient. One avenue for identifying intrinsic-based strategies
that may enhance the regenerative potential of peripheral
neurons as an adjuvant therapy after complex injuries has
been to study the underlying mechanisms involved in the
conditioning PN lesion, or simply the conditioning lesion.
This powerful tool has provided a greater understanding of
the molecular mechanisms responsible for the differences in
regenerative potential between the two axonal branches of the
bipolar dorsal root ganglion neuron.The conditioning lesion
describes the phenomenon of the enhanced regenerative
potential that is acquired by the central branch of a dorsal
root ganglion neuron after the peripheral branch is injured,
through the activation of specific intrinsic growth signaling
programs. The central branch can then regenerate into and
beyond a lesion when made in the CNS, even overcoming
the inhibitory environment of the spinal cord [48–50]. In
2002, Cai et al. demonstrated that one of the key components
of the conditioning lesion was to raise cyclic AMP levels in
the injured neuronal somata, allowing the axons to then be
able to overcomeMAG inhibition of elongation by triggering
a transcription-dependent rise in regeneration-associated
genes [25], such as the expression of arginase 1 [51].
Soon after cyclic AMP signaling was implicated as a main
effector in the conditioning paradigm, it was demonstrated
that intraganglionic injection of a membrane permeable
cyclic AMP analog, dibutyryl cyclic AMP (db-cyclic AMP),
could mimic the effects of a conditioning lesion and that this
effect occurred through activation of PKA [20, 52]. Similar to
this phenomenon in PN injury, intraocular injection of db-
cyclic AMP has been shown to enable optic nerve growth
after optic nerve injury, implicating cyclic AMP signaling
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as an important event in the induction of intrinsic axon
growth programs in both peripheral and central neuron
populations [48, 53–55]. Although methods to raise cyclic
AMP by the injection of an analog can replicate to some
extent the conditioning paradigm, it does not completely
provide the same degree of regenerative benefit and does not
produce sustained axon regeneration when given as a single
injection [52, 53, 56]. This lack of sustained regenerative
capacity illustrates the need for a better understanding of
the downstream signaling, pathway crosstalk, and the timing
and subcellular compartmentalization of cyclic AMP in
stimulating intrinsic axon growth initiation and elongation.
Being a second messenger important in many biological
processes, it is not surprising that cyclic AMP is involved
in a variety of signaling pathways that mediate PN regen-
eration. However, it is in the role that cyclic AMP plays
as a simultaneous mediator of both the intrinsic ability of
axons to regenerate as well as releasing environmental growth
inhibition, in both the PNS and CNS, that the activation
of the cyclic AMP pathway in the PNS is unique. With
roles for cyclic AMP also at the axonal growth cone and
within SCs at the periphery, which are important for guiding
and remyelinating the regrowing axon, integrating these
responses andmaximizing them for the greatest degree of PN
repair remain important therapeutic considerations.
5. Targeting the Cyclic AMP Pathway for
PN Regeneration
Currently, the main focus for therapeutics in PN repair is
the use of artificial nerve guidance channels to match or
exceed the performance of the gold standard, an autograft.
To date, the use of molecular or pharmacological methods to
increase the intrinsic capacity of injured PNs to regenerate
has remained within the arena of experimental research.
In animal PN lesion models, enhancing the production or
inhibiting themetabolism of cyclic AMPhave been employed
for therapeutic effect. Adenylate cyclase activators, cyclic
AMP analogs, and phosphodiesterase (PDE) inhibitors have
all been employed to promote PN repair using primarily
pharmacological agents. In 1987, Kilmer and Carlsen first
demonstrated that the daily injection or delivery of forskolin
through an implanted osmotic pump produced a sustained
40% increase in the rate of sensory nerve regeneration
and an approximately 40-fold greater elevation in neuronal
cyclic AMP than an equimolar concentration of a control,
isoprenaline, after freeze-lesioning of the sciatic nerve. Three
years later the same group tested the hypothesis that cyclic
AMP modulates nerve regeneration in mammals by com-
paring the effects of chronically infused forskolin with that
of infused db-cyclic AMP, 8-bromo cyclic AMP, or the PDE
inhibitor, theophylline, in hamsters [57]. The results from
these studies demonstrated that all methods targeting cyclic
AMP elevation were able to enhance regeneration, though
forskolin and 8-bromo cyclic AMP had the most profound
effect on axonal elongation, and theophylline produced the
largest decrease in the initiation time required for neu-
rite sprouting. Interestingly the effect of theophylline was
mirrored by caffeine, a methylxanthine that can increase
intracellular calcium but also has a limited ability to inhibit
PDEs [57]. However, in these studies the relative levels of
increased cyclic AMP among the different approaches were
not investigated and thus it is not clear whether such an effect
may have accounted for their different levels of potency on
PN regeneration.
In later studies it was found that while forskolin alone was
sufficient to increase cyclic AMP levels in normal nerve and
following nerve crush during the period of axon regeneration,
it could not do so if the nerve had been transected [58].
Following nerve transection, cyclic AMP could only be
elevated by the combination of forskolin (to activate adenylyl
cyclase) and 3-isobutyl-1-methylxanthine (IBMX), a general
inhibitor of PDEs, which hydrolyze cyclic AMP. It was
suggested in this work that PDE inhibition was necessary
in order to elevate cyclic AMP levels in nonmyelinating
nerves, which exhibited a robust induction of PDE activity
[58]. Subsequent experiments demonstrated that the PDE4
inhibitor Rolipramwas very effective in enhancing PN regen-
eration after injury and that not only was Rolipram treatment
alone sufficient for promoting PN regeneration, but it also
accelerated the reinnervation of denervated skeletal muscles
[59, 60].The effect of cyclic AMP on PN regeneration appears
to involve intermediaries both directly downstream of its
effector pathways, PKA and EPAC, as well as from crosstalk
between cyclic AMP and other signaling cascades, such as
the Rho-A/ROCK pathway. Studies have shown that one
growth promoting effect of cyclic AMP is to antagonize Rho-
A GTPase signaling, which has been implicated in growth
cone collapse as well as in the intracellular transmission
of signals from axon growth inhibitory molecules, such as
myelin [52]. While the involvement of the Rho-A GTPase
and downstream ROCK in axon growth inhibition has been
best characterized in models of CNS injury, such as spinal
cord injury [52], work in PN regeneration failure has also
focused on this pathway. Cheng and colleagues [30] reported
that the activation of GTP-bound Rho-A, which is normally
undetectable in intact ganglia, was dramatically upregu-
lated in both neuronal soma and axons after injury. Later,
Huelsenbeck et al. [61] employed Clostridium botulinum C3-
exoenzyme to nonenzymatically downregulate active Rho-
A after PN crush. Inhibition of Rho-A would promote
axon growth via disinhibition of cytoskeletal assembly medi-
ated by ROCK. They demonstrated that daily or a one-
time topical application of a 26-amino-acid fragment of C3
after PN crush or in a nerve autotransplantation paradigm,
respectively, in rat resulted in improved axonal elongation
and faster motor recovery [61]. Interestingly, a study by
Auer and colleagues [62], using a C3 mutant exoenzyme that
lacked RhoA inhibitory activity, showed that this deficient C3
could also promote axonal growth, suggesting that effectors
other than Rho-A may be involved in such responses. Other
studies employing the ROCK inhibitor Fasudil have shown
that this compound can promote PN repair after injury
as measured by increased amplitude recordings of distally
evoked compound muscle action potentials [30, 31].
Although much of the work aimed at increasing cyclic
AMP after PN injury has focused on pharmacological
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approaches, alternative strategies to enhancing cyclic AMP
for PN repair do exist, in particular the use of electrical
stimulation. In the 1980s it was reported that low frequency
electrical stimulation of PNs after crush injury could acceler-
ate the return of reflex foot withdrawal and contractile force
in reinnervated legmuscles [63, 64]. Al-Majed and colleagues
later demonstrated that electrical stimulation of the lacerated
and graft repaired rat femoral nerve using the same low
frequency stimulation could accelerate sensory axon growth
and direct axons specifically into their correct sensory nerve
pathways [65]. In later work they would show that such
accelerated growth in response to low frequency electrical
stimulation required cyclic AMP and PKA activation [66].
6. Conclusions and the Future of Targeting
Cyclic AMP for PN Repair
In summary, following PN injury, cyclic AMP serves a
crucial role in activating many of the signaling pathways that
ultimately produce functional nerve regeneration. This sec-
ond messenger, by way of various transcription-dependent
pathways, promotes axonal growth and myelination, as
well as SC proliferation and differentiation. Transcription-
dependent pathways leading to axonal growth depend largely
on activation of CREB and the inhibition of cytoskeletal
inhibitors by PKA. While SC proliferation has been found to
be PKA dependent and differentiation and myelination have
been found to be EPAC dependent, both these pathways are
nevertheless ultimately cyclic AMP-activation dependent, in
what are no longer considered opposing pathways.
Pharmacological and nonpharmacological strategies tar-
geting cyclic AMP and its upstream or downstream effectors
have shown promise for management of PN injury. Such
utilization of cyclic AMP-dependent pathways to enhance
PNS recovery would complement the extrinsic approach of
surgical modalities utilized in clinical practice today, pro-
viding a more holistic and potentially efficacious therapeutic
approach to neuroregeneration of PN injury.
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